Subscribe To
DSGN / Why Shares of Design Therapeutics Are Plummeting on Tuesday
DSGN News
By The Motley Fool
August 15, 2023
Why Shares of Design Therapeutics Are Plummeting on Tuesday
Design focuses on therapies to treat neurological disorders. The company said it has enough cash to fund operations through 2026. more_horizontal
By Market Watch
August 15, 2023
Design Therapeutics stock plunges on trial results for neuromuscular disease treatment
Shares of Design Therapeutics Inc. DSGN dropped 45% in premarket trading Tuesday after the biopharma company reported mixed results from an early-stag more_horizontal
By GlobeNewsWire
May 31, 2023
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
CARLSBAD, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatme more_horizontal
By Benzinga
January 19, 2022
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target. The analyst Madhu Kumar ha more_horizontal
By Benzinga
January 19, 2022
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target. The analyst Madhu Kumar ha more_horizontal
By Benzinga
January 19, 2022
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target. The analyst Madhu Kumar ha more_horizontal